1. The Effect of Tolvaptan on BP in Polycystic Kidney Disease
- Author
-
Judith E Heida, Jennifer H. Lee, Hui Li, Vicente E. Torres, Ron T. Gansevoort, John Ouyang, Ronald D. Perrone, Arlene B. Chapman, Olivier Devuyst, University of Zurich, Gansevoort, Ron T, Groningen Kidney Center (GKC), and Cardiovascular Centre (CVC)
- Subjects
Nephrology ,medicine.medical_specialty ,Mean arterial pressure ,2727 Nephrology ,business.industry ,Tolvaptan ,Urology ,Autosomal dominant polycystic kidney disease ,610 Medicine & health ,General Medicine ,medicine.disease ,Placebo ,10052 Institute of Physiology ,Blood pressure ,Internal medicine ,Post-hoc analysis ,medicine ,Polycystic kidney disease ,570 Life sciences ,biology ,business ,medicine.drug - Abstract
Background: The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP via various acute and chronic effects. Methods: To investigate the magnitude and time course of the effect of tolvaptan use on BP, we conducted a post hoc study of the TEMPO 3:4 trial, which included 1445 patients with autosomal dominant polycystic kidney disease randomized 2:1 to tolvaptan or placebo for 3 years. We evaluated systolic and diastolic BP, mean arterial pressure, hypertension status, and use and dosing of antihypertensive drugs over the course of the trial. Results: At baseline, BP did not differ between study arms. After 3 weeks of tolvaptan use, mean body weight had decreased from 79.7 to 78.8 kg, and mean plasma sodium increased from 140.4 to 142.6 mmol/L (both P
- Published
- 2021
- Full Text
- View/download PDF